FridayMay 15, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention

Research supports the urgent need for more effective tools to identify the risk of cardiovascular disease earlier and guide personalized intervention strategies. Cardio Diagnostics’ solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care. This emphasis on prevention aligns with growing recognition that earlier intervention can significantly improve long-term outcomes. Most people are aware that cardiovascular disease (“CVD”) is the leading cause of death in the United States; what they might not know is that an estimated 80% of those cases are considered preventable through earlier detection and proactive management of key risk factors. This highlights the urgent…

Continue Reading

FridayMay 15, 2026 10:00 am

Wastewater Monitoring Could Help in Early Prediction of Influenza Outbreaks

Seasonal influenza often spreads rapidly, and timely data can help policymakers and the health care system make the right decisions on matters like resource planning. A new study conducted in Japan suggests that monitoring wastewater could be a helpful way of learning in advance how influenza outbreaks are likely to manifest a week before data on patients affected flag outbreak trends. The study, conducted by an Osaka University-based team led by Prof. Michio Murakami, found that measuring the viral RNA of the influenza virus in wastewater can help teams to accurately estimate the incidence of influenza in communities. Such estimates…

Continue Reading

FridayMay 15, 2026 9:00 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) CEO Highlights AI Voice Detection Platform and Workplace Rollout Plans During TechMediaWire Podcast

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. During a recent TechMediaWire Podcast appearance, Justin Hanka outlined MindBio Therapeutics’ progress in developing advanced AI-driven voice analysis technology for drug and alcohol intoxication detection. MindBio Therapeutics Corp. says its prediction models are trained using more than 50 million data points collected through years of clinical and behavioral research. The company’s initial commercial strategy focuses on workplace safety sectors including mining, aviation, and construction, where impairment-related incidents carry significant operational and regulatory risks. Hanka said during the interview that the company’s voice-analysis platform can detect not…

Continue Reading

ThursdayMay 14, 2026 10:00 am

Study Suggests Testosterone Slows Glioblastoma Progression in Men

New research funded by the NIH has uncovered a link between androgens in men and brain tumors. The preclinical study found that men with low levels of testosterone tended to have shorter survival times when diagnosed with glioblastoma when compared to those that had higher levels of this male sex hormone.  Glioblastoma is the deadliest form of brain cancer and kills most of its victims in a matter of months. This new study opens the possibility that men with lower testosterone levels tend to have their GBM tumors growing at a faster pace than similar tumors in men with higher levels of testosterone.…

Continue Reading

TuesdayMay 12, 2026 9:00 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano has transitioned into a pharmaceutical-focused platform anchored by its patented GEP-44 peptide targeting metabolic disease. Preclinical data for GEP-44 demonstrates meaningful weight loss, improved glucose control, and a favorable tolerability profile relative to existing GLP-1 therapies. The company’s vertically integrated model combines therapeutic development with delivery technologies, supporting differentiation through potential non-injectable formats. SureNano is advancing GEP-44 through a defined regulatory pathway, including IND-enabling studies and planned clinical trials. The company provides exposure to the expanding GLP-1 and obesity treatment markets, which…

Continue Reading

MondayMay 11, 2026 11:15 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy. The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes. The company is…

Continue Reading

MondayMay 11, 2026 10:30 am

The Partnership Playbook: Oncotelic Therapeutics Inc. (OTLC) Advancing Its Pipeline Without Dilution

The GMP Bio joint venture contributed a $249 million increase to Oncotelic’s balance sheet through independent third-party valuation The company is leveraging a deep intellectual property portfolio, including more than 500 patent applications and 75 issued patents Oncotelic’s PDAOAI platform has integrated approximately 28 million scientific abstracts and is advancing toward commercial deployment with robotics integration In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital. Advancing multiple therapeutic candidates through preclinical work, clinical trials, and regulatory approval requires sustained funding, and traditional financing routes often come at the cost of dilution or loss of asset control.…

Continue Reading

ThursdayMay 07, 2026 10:30 am

Pipeline Maturity is Redefining Valuations in Biotech

The biotechnology industry is going through a transformation that is redefining how a company’s value is interpreted. While revenue has traditionally been highly associated with a company’s valuation, clinical-stage progression and a company’s probability of success are being increasingly factored into its valuation. Companies on the front lines of this shift, such as Oncotelic Therapeutics, are leveraging their expertise in the space, and showing how scientific advancement can influence financial positioning. The biotechnology sector is undergoing a meaningful shift in how companies are evaluated, challenging long-standing assumptions about value creation. Traditionally, valuation has been closely tied to revenue generation and…

Continue Reading

ThursdayMay 07, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Files Patent Applications for Voice-Based Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The company has filed patent applications covering 15 novel discoveries in AI-driven voice intoxication detection. The platform analyzes speech patterns to estimate drug and alcohol impairment without physical samples. Initial commercial rollout is targeting mining and aviation via Edge AI kiosk systems, with Broader applications including call centers, law enforcement, and mental health screening. Technology is designed for high-volume, regulated environments where testing is costly and time consuming. The overall global drug and alcohol testing market is projected to reach $4.2 billion by 2033. MindBio Therapeutics…

Continue Reading

TuesdayMay 05, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions

Cardiovascular disease remains the leading cause of death in the United States. One of the most persistent challenges in cardiac care is patient delay in seeking care. HeartBeam is working to address this gap by transforming how ECG data are collected and used through its HeartBeam System. Cardiovascular disease continues to be a major global health challenge, driven by aging populations, lifestyle factors and persistent gaps in early detection that continue to challenge healthcare systems. In response to these trends, HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000